Peptide Bio IndexEvidence first. Hype last.
⌕

Semax BDNF and Gene-Expression Research

Written by

in

Peptide Research Overviews
PBIPeptide Bio Index Editorial DeskSource-labeled research summary
Source-limited9 min readUpdated Sep 2, 2026
Jump to a section
  1. What Semax is and its neurotrophic associations
  2. Evidence linking Semax to BDNF and neurotrophic pathway modulation
  3. Transcriptomic (RNA‑Seq) results in rodent ischemia models
  4. Other molecular targets and mechanistic findings
  5. Human functional imaging evidence
  6. Evidence gaps, translational limits, and research needs
  7. Reported study-design details from cited sources
  8. Limitations and research gaps
  9. Documentation checklist
  10. Related research supplies
  11. More Semax research
  12. Sources and references

Disclosure: Peptide Bio Index is affiliated with SourcePoint Research and may earn from qualifying purchases or affiliate links.

This article summarizes published research and reported study designs. It is not medical advice, dosing guidance, or a personal-use recommendation.

Source-limited research note: The reviewed sources were incomplete, ambiguous, or insufficient for a normal article. This page labels missing details rather than guessing.

This deep dive summarizes reviewed evidence linking Semax (an ACTH-derived heptapeptide) to BDNF-related neurotrophic signaling and to transcriptomic regulation in brain injury models, and it highlights other molecular targets implicated by recent mechanistic studies.

What Semax is and its neurotrophic associations

Semax is a synthetic heptapeptide (sequence Met‑Glu‑His‑Phe‑Pro‑Gly‑Pro) based on an ACTH fragment; it is described in the literature as a neuroactive/neuroprotective peptide that has been associated with enhancement of brain-derived neurotrophic factor (BDNF) and related neurotrophic pathways in review-level mechanistic summaries. [S7] [S1]

Evidence linking Semax to BDNF and neurotrophic pathway modulation

A narrative review characterizes Semax among neuroactive peptides that enhance BDNF and HGF/c‑Met pathways relevant to neuroplasticity and repair; transcriptomic studies in rodent ischemia models report peptide-associated changes in growth factor–related and neurogenesis‑associated genes, providing molecular-level evidence of effects on trophic and signaling networks. [S1] [S6] [S8]

Transcriptomic (RNA‑Seq) results in rodent ischemia models

In a rat transient middle cerebral artery occlusion (tMCAO) model, RNA‑Seq at 24 h after tMCAO identified 3,774 DEGs caused by ischemia; Semax administration was associated with 1,539 DEGs and acted to reduce ischemia‑related expression distortions for 1,171 genes (genes linked to immune and neurosignaling pathways were highlighted), and the peptide induced DEGs related to neurogenesis, angiogenesis, protein kinases, and growth factors; the pattern of transcriptomic action differed by timepoint when compared with an earlier 4.5 h post‑tMCAO analysis. [S6]

Using the same experimental animals, analysis of the striatum (a region with more severe ischemic focus) showed fewer DEGs under peptide treatment than in frontal cortex; both Semax and a related ACTH(6‑9)PGP peptide tended to normalize hundreds of ischemia‑disrupted genes in the striatum but ACTH(6‑9)PGP produced additional changes in ~152 genes associated predominantly with inflammation; roughly a hundred genes overlapped between peptides and regions and were linked mainly to neuroactive ligand–receptor interaction. [S8]

Other molecular targets and mechanistic findings

In a mouse spinal cord injury model, Semax was reported to improve functional recovery and to inhibit lysosomal membrane permeabilization–related pyroptosis and oxidative stress; RNA‑Seq and complementary analyses implicated regulation of the deubiquitinating enzyme USP18 and suggested interaction with the μ‑opioid receptor, with downstream effects on deubiquitination of FTO proposed as a mechanistic link. In vitro work also shows that chemical modifications of Semax (N‑terminal acetylation) alter Cu(II) coordination chemistry and that the presence of the free N‑terminal amino group is important for cellular protection against Cu(II) toxicity in SH‑SY5Y neuroblastoma cells. [S3] [S7]

Human functional imaging evidence

A functional‑connectivity fMRI study in 52 healthy volunteers examined acute effects of an injection of Semax (compared with Selank and placebo) using scans before and at 5 and 20 minutes after injection; between‑group differences were observed in resting‑state connectivity between the right amygdala and right temporal cortex (including fusiform, inferior/middle temporal and parahippocampal gyri), indicating acute changes in brain network functional connectivity without direct measurement of BDNF in that study. [S2]

Evidence gaps, translational limits, and research needs

Narrative reviews and the primary literature emphasize that most Semax evidence is preclinical (rodent and in vitro) and that clinical trial data remain limited; key gaps include scarcity of controlled clinical trials, incomplete reporting of dosing/administration parameters in many preclinical reports, limited longitudinal data, and uncertainty about how transcriptomic signatures translate to durable functional outcomes in humans. [S1] [S4]

Reported study-design details from cited sources

The following table summarizes protocol details reported in cited studies. These details are provided as literature context only and are not recommendations or instructions.

Source Study Type Model / Subject Amount Reported Route Reported Frequency Duration Notes
[S2] Journal Article; human fMRI study healthy human volunteers (n=52) not reported in the reviewed source injection single administration with imaging at baseline, 5 min, and 20 min post‑injection (study scans at those timepoints) observations up to 20 minutes post‑injection Resting‑state fMRI assessed connectivity changes between predefined ROIs (e.g., amygdala, DLPFC); amount not reported in the reviewed source.
[S3] Journal Article; animal (mouse) spinal cord injury study female C57BL/6 mice with spinal cord injury at T9‑T10 not reported in the reviewed source not reported in the reviewed source not reported in the reviewed source functional recovery assessed during post‑injury follow‑up using behavioral and histochemical methods (timepoints not specified in excerpt) Outcomes included footprint analysis, Basso scores, inclined plane tests, histology, immunofluorescence, Western blot, RT‑qPCR, TEM, RNA‑seq and network pharmacology; implicated USP18 and μ‑opioid receptor. Amount not reported in the reviewed source.
[S6] Journal Article; animal (rat) ischemia model with RNA‑Seq rat frontal cortex (penumbra) after transient middle cerebral artery occlusion (tMCAO) not reported in the reviewed source not reported in the reviewed source not reported in the reviewed source RNA‑Seq analysis performed at 24 h after tMCAO (comparison to earlier 4.5 h timepoint reported) Ischemia produced 3,774 DEGs; Semax associated with 1,539 DEGs at 24 h and normalized expression distortions for 1,171 genes. Amount not reported in the reviewed source.
[S8] Journal Article; animal (rat) ischemia model with region‑specific RNA‑Seq rat striatum from same animals used for frontal cortex tMCAO analysis not reported in the reviewed source not reported in the reviewed source not reported in the reviewed source samples taken and RNA‑Seq analysis at 24 h after tMCAO Fewer DEGs observed in striatum than frontal cortex; peptides normalized hundreds of DEGs and ACTH(6‑9)PGP produced ~152 additionally affected genes linked to inflammation; ~100 genes overlapped between peptides/regions. Amount not reported in the reviewed source.
[S7] Journal Article; in vitro biochemical/cell study SH‑SY5Y human neuroblastoma cell line (in vitro) not reported in the reviewed source in vitro application not reported in the reviewed source not reported in the reviewed source Study examined N‑terminal acetylation effects on Cu(II)/Zn(II) coordination and cellular protection; Ac‑Semax altered metal coordination and did not protect SH‑SY5Y cells from Cu(II) toxicity, implicating the free NH2 terminus in cell protection. Amounts/concentrations not reported in the reviewed excerpt.

Limitations and research gaps

  • Most mechanistic and transcriptomic evidence for Semax comes from rodent ischemia or acute injury models and from in vitro assays; human interventional data are limited to acute imaging endpoints in small cohorts.
  • Dosing, route, frequency, and exact administration details are not consistently reported in the reviewed excerpts, limiting protocol interpretation.
  • RNA‑Seq DEG counts and pathway associations are context- and timepoint‑dependent (e.g., 4.5 h vs 24 h post‑ischemia) and should not be equated with clinical efficacy.
  • Direct measurements of BDNF protein changes in human subjects were not available in the reviewed sources.

Documentation checklist

  • Confirm whether a given finding is from human, animal, or in vitro data before interpreting translational relevance.
  • Verify reported timepoints and tissues when comparing transcriptomic outcomes (e.g., 4.5 h vs 24 h post‑ischemia).
  • Look for explicit dosing, route, and administration schedules in the primary source; absence of those details limits protocol interpretation.
  • Distinguish gene-expression signatures (RNA-Seq/DEG counts) from measured functional or behavioral outcomes in the same study.
  • When evaluating clinical relevance, prioritize controlled human trials over acute imaging or isolated preclinical models.
  • RNA‑Seq library preparation kits and indexing adapters (documentation and labeling)
  • Sample storage cryovials and -80°C inventory boxes
  • fMRI‑compatible head stabilization and monitoring documentation
  • Bioinformatics workstation with RNA‑Seq alignment and differential-expression software (documentation)

Research organization supplies: Common tools used for research documentation workflows may include lab notebooks, label makers, sample storage boxes, inventory stickers, and temperature log sheets.

Paid-link disclosure: Peptide Bio Index may earn a commission from qualifying purchases. As an Amazon Associate I earn from qualifying purchases.

Batch and inventory labeling

Phomemo M110 Label and Barcode Printer

A compact thermal label printer for inventory identifiers, storage-box labels, batch references, and document-folder organization.

View on Amazon (paid link)

Label-printer refill

Phomemo M110 White Replacement Labels

White 1.57 × 0.78 inch replacement labels for compatible Phomemo printers. Confirm printer and label-size compatibility before ordering.

View on Amazon (paid link)

Product listings, specifications, and availability can change. Review the current Amazon listing and manufacturer instructions before ordering. These links are for research organization and compatible surface/equipment-cleaning workflows, not personal-use guidance.

Research Supply Note: For research-use-only sourcing, review current SourcePoint Research inventory and batch documentation at SourcePointResearch.com. Peptide Bio Index is affiliated with SourcePoint Research.

More Semax research

Sources and references

  1. [S1] Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.. Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews. 2026. PMID: 41490200. DOI: 10.5435/JAAOSGlobal-D-25-00236
  2. [S2] Panikratova YR, Lebedeva IS, Sokolov OY, Rumshiskaya AD, Kupriyanov DA, Kost NV. Functional Connectomic Approach to Studying Selank and Semax Effects.. Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections. 2020. PMID: 32342318. DOI: 10.1134/S001249662001007X
  3. [S3] Liu R, Chen Y, Huang H, Li X, Lv J, Jiang L. Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice.. British journal of pharmacology. 2025. PMID: 40692165. DOI: 10.1111/bph.70122
  4. [S4] Mavrych V, Shypilova I, Bolgova O. Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.. Frontiers in aging. 2026. PMID: 42021992. DOI: 10.3389/fragi.2026.1790247
  5. [S5] Tarasov VV, Kudryashov NV, Chubarev VN, Kalinina TS, Barreto GE, Ashraf GM. Pharmacological Aspects of Neuro-Immune Interactions.. Current pharmaceutical design. 2018. PMID: 28875850. DOI: 10.2174/1381612823666170829135115
  6. [S6] Filippenkov IB, Shpetko YY, Stavchansky VV, Denisova AE, Gubsky LV, Andreeva LA. ACTH-like Peptides Compensate Rat Brain Gene Expression Profile Disrupted by Ischemia a Day After Experimental Stroke.. Biomedicines. 2024. PMID: 39767736. DOI: 10.3390/biomedicines12122830
  7. [S7] Magrì A, Tabbì G, Giuffrida A, Pappalardo G, Satriano C, Naletova I. Influence of the N-terminus acetylation of Semax, a synthetic analog of ACTH(4-10), on copper(II) and zinc(II) coordination and biological properties.. Journal of inorganic biochemistry. 2016. PMID: 27586814. DOI: 10.1016/j.jinorgbio.2016.08.013
  8. [S8] Filippenkov IB, Shpetko YY, Ales DA, Stavchansky VV, Denisova AE, Yuzhakov VV. Genes That Associated with Action of ACTH-like Peptides with Neuroprotective Potential in Rat Brain Regions with Different Degrees of Ischemic Damage.. International journal of molecular sciences. 2025. PMID: 40650034. DOI: 10.3390/ijms26136256

Peptide Bio Index is affiliated with SourcePoint Research. Articles may link to SourcePointResearch.com and third-party affiliate products. As an Amazon Associate, Peptide Bio Index earns from qualifying purchases. Content is educational and research-literature focused only and is not medical advice, dosing guidance, or a personal-use recommendation.

More posts